References

Chemo Secrets From a Breast Cancer Survivor

Breast Cancer Survivors

Get Instant Access

1. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999;77:266.

2. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999;94:448.

3. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840.

4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848.

5. Michallet M, Archimbaud E, Rowlings PA, et al. HLA-identical sibling bone marrow transplants for chronic lymphocytic leukemia. Ann Intern Med 1996;124:311.

6. Khouri I, Przepiorka D, van BK, et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997;97:466.

7. Rabinowe SN, Soiffier RJ, Gribben J et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic leukemia. Blood 1993;4:1366.

8. Dreger P, von Neuhoff N, Kuse R, et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer 1998;77: 2291.

9. Milligan DW, Davies FE, Morgan GJ, et al. Fludarabine followed by stem cell autografting for younger patients with CLL: preliminary results from the MRC pilot study. Bone Marrow Transplant 1999;23(suppl 1):S53.

10. Pavletic S, Khouri I, King R, et al. HLA-matched unrelated donor (MUD) bone marrow transplantation for B-cell chronic lymphocytic leukemia (results from the CLL Working Group, National Marrow Donor Program) [abstract]. Proc ASCO 2000;19:4a.

11. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000;25:717.

12. Esteve J, Villamor N, Colomer D, et al. Different significance of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic and therapeutic implications. Blood 2001;98(suppl 1).

13. Michallet M, van Biezen A, Bandini G, et al. Analysis of prognostic factors on the outcome of autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood 2001;98:859a.

14. Esteve J, Montserrat E, Dreger P, et al. Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): outcome and prognostic factors after autologous and allogeneic transplants. [abstract]. Blood 2001;98(suppl 1): 482a.

15. Van Biesen K, Keralavarma B, Devine S, Stock. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia 2001,15:1317.

16. Mehta J, Powles R, Singhal S, Iveson T, Treleaven J, Catovsky D. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996;17:371.

17. Rondon G, Giralt S, Huh Y, et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996;18:669.

18. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390.

19. Schetelig J, Held TK, Bornhäuser M, et al. Nonmyeloablative allogeneic stem cell transplantation in chronic lymphocytic leukemia from related and unrelated donors [abstract]. Blood 2000;96 (suppl 1):200a.

20. Mackinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol 2000;110:12.

21. Martino R, Caballero MD, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001;115:653.

22. Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002;99:75.

23. Perez-Simon JA, Kottaridis P, Martino R, et al. Reduced-intensity conditioning with or without CAMPATH-1: comparison between two prospective studies in patients with lymphoproliferative disorders [abstract]. Blood 2001;98:743a.

24. Dreger P, Glass B, Seyfarth B, et al. Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma after failure of autologous SCT. Bone Marrow Transplant 2000;26:1361.

25. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817.

26. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756.

27. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234.

28. Provan D, Bartlett-Pandite L, Zwicky C et al. Eradication of PCR detectable chronic lymphocytic cells is associated with improved outcome after bone marrow transplanation. Blood 1996;88:2228.

29. Dreger P, von Neuhoff N, Sonnen R, et al: Factors determining feasibility and outcome of autologous stem cell transplantation for CLL. Ann Oncol 1999;10(suppl 3):72.

30. Milligan DW, Davies FE, Morgan GJ et al. Fludarabine followed by stem cell autografting for younger patients with CLL: preliminaryresults from MRC pilot study. Bone Marrow Transplant 1999;23(suppl 1):S53.

31. French Cooperative Group on Chronic Lymphocytic Leukemia. Effectiveness of CHOP regimen in advanced untreated chronic lymphocytic leukemia. Lancet 1986;1:1346.

32. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165.

33. Michallet M, Apperley J. Peripheral blood progenitor cell mobilisation and transplantation after fludarabine therapy in chronic lymphocytic leukemia in Europe. Bone Marrow Transplant 1997;19(suppl 1):S146.

34. Scime R, Indovina A, Santoro A, et al. PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. Bone Marrow Transplant 1998;22:1159.

35. Paulus U, Schmitz N, Viehmann K, et al: Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL. Bone Marrow Transplant 1997;20:415.

36. Dreger P, Van Biezen A, Brand R, et al. Allogeneic stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL) using intensity-reduced conditioning: a survey of the European Blood and Marrow Transplant Group (EBMT). Blood 2001;98:3095a.

37. Baccarani L, Cavo M, Gobbi M, Lauria F, Tura S. Staging of chronic lymphocytic leukemia. Blood 1982;591191.

38. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. Br J Haematol 1986;62:567.

39. Molica S, Alberti A. Prognostic value of lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987;60:567.

40. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S. The serum ß2 microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia. Blood 1995;86(suppl 1):606a.

41. Sawitsky A, Rai KR, Glidewell O, et al. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977;50:1049.

42. Knospe WH, Loeb V, Huguley CM, et al. Bi-weekly chlorambucil of chronic lymphocytic leukemia. Cancer 1974;33:555.

43. Keller JW, Knospe WH, Raney M, et al. Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. Cancer 1986;58:1185.

44. Montserrat E, Alcala A, Parody R, et al. Treatment of chronic lymphocytic leukemia in advanced stages—a randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine and prednisone. Cancer 1985;56:2369.

45. Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone as initial treatment for chronic lymphocytic leukemia. Long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991;9:770.

46. French Cooperative Group on Chronic Lymphocytic Leukemia. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. Leuk Lymphoma 1994;13:449.

47. Keating MJ, Scouros M, Murphy S, et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988;2:391.

48. Keating MJ, Hester JP, McCredie KB, et al. Long-term results of CAP therapy in chronic lymphocytic leukemia. Leuk Lymphoma 1990;2:391.

49. Kempin S, Lee BJ III, Thaler HT, et al. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan and prednisone). Blood 1982;60:1110.

50. Keating MJ, Kantarjian MJ, O'Brien S, et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukaemia. J Clin Oncol 1991;9:44.

51. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993;82:1695.

52. Robertson LE, O'Brien S, Kantarjian H, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995;9:1444.

53. Hiddemann W, Rottmann R, Woermann B, et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine—results of a clinical phase II study. Ann Hematol 1991;63:1.

54. Montserrat E, Lopez-Lorenzo JL, Manso F, et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia—The Spanish Group experience. Leuk Lymphoma 1996;21:467.

55. Gjedde SB, Hansen MM. Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia. Leuk Lymphoma 1996;21:317.

56. Puccio CA, Mittelman A, Lichtman SM, et al. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 1991;9:1562.

57. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992;327:1056.

58. Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 1991;5(suppl 1):133.

59. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989;7:433.

60. Saven A, Lemon RH , Kosty M, Beutler E, Piro LD. 2-Chlorodeoxydeadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995;13:570.

61. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319.

62. Cazin B, Maloum K, Divine M, et al (French Cooperative Group for CLL). Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 59 patients. Blood 2001;98:3214a.

63. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukaemia. Blood 1999;94:2836.

64. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:2245.

65. Gratwohl A, Passweg J, Baldomero H, et al. Blood and marrow transplantation activity in Europe 1996. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1998;22:227.

66. Gribben JG, Neuberg D, Soiffer RJ, et al: Autologous versus allogeneic bone marrow transplantation for patients with poor prognosis CLL. Blood 1998;92:322a.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment